5 Key Takeaways

• 1

  Everest Medicines has signed an asset purchase agreement with Corxel Pharmaceuticals to develop LNZ100 for presbyopia in Greater China.

• 2

  LNZ100, a 1.44 percent aceclidine solution, aims to improve near vision by inducing pupil constriction without affecting distance vision.

• 3

  The therapy was approved in the US in July 2025 and is expected to receive approval in China by the first quarter of 2027.

• 4

  A Phase 3 trial involving 300 participants demonstrated LNZ100's efficacy, showing significant improvements in near vision.

• 5

  Presbyopia affects nearly 100% of individuals by age 52 in China, with current treatment options being limited and often inconvenient.